Objective To systematically evaluate the efficiency and safety of Vandetanib plus Docetaxel versus Docetaxel alone for advanced non-small cell lung cancer (NSCLC). Methods The randomized controlled trials (RCTs) of Vandetanib plus Docetaxel versus Docetaxel for NSCLC published before October 26, 2010 were searched in EMbase, The Cochrane Library, PubMed, Wanfang database, VIP Database, China National Knowledge Infrastructure(CNKI), and China biological medical literature database. The methodological quality of the included studies was evaluated according to the Cochrane assessment handbook 5.0.2, and the meta-analysis was conducted by using RevMan 5.0 software. Results A total of 3 RCTs involving 1 626 patients were included. The meta-analysis showed that there were positive effects between the Vandetanib group and the control group in the overall response rate (OR=1.81, 95%CI 1.37 to 2.38, Plt;0.000 1), disease control rate and 1-year survival rate; and all studies showed that Vandetanib could significantly lengthen the progression-free survival. Conclusion The Vandetanib group is superior to the control group for its better effectiveness and fewer adverse effects, and it is worth referring and applying in clinic.
